AMLX - Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3 Follows Securities Class Action Complaint – Hagens Berman | Benzinga

SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors who suffered substantial losses to submit your losses now.

Class Period: Nov. 11, 2022 – Nov. 8, 2023
Lead Plaintiff Deadline: Apr. 9, 2024
Visit: www.hbsslaw.com/investor-fraud/amlx
Contact An Attorney Now: AMLX@hbsslaw.com
844-916-0895

Amylyx Pharmaceuticals, Inc. (AMLX) Securities Fraud Class Action:

On March 8, 2024, Amylyx announced that topline results from its Global Phase 3 PHOENIX Trial of its product intended to treat patients with Lou Gehrig's disease -- RELYVRIO -- did not meet its primary endpoint of reaching statistical significance, "nor was there statistical significance seen in secondary endpoints."

This news sent the price of Amylyx shares crashing $16.27, or about 85% lower, during intraday trading on March 8, 2024.

The news follows the filing of a securities fraud class action complaint, which alleges that Amylyx made false and misleading statements and failed to disclose that: (1) it overstated RELYVRIO's commercial prospects; (2) patients were discontinuing treatment ...

AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman>Full story available on Benzinga.com